News
Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback